BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS. Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist. 2014;19:868-879. [PMID: 25001265 DOI: 10.1634/theoncologist.2014-0097] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Li WZ, Liang ZW, Cao Y, Cao TT, Quan H, Yang ZY, Li Q, Dai ZT. Estimating intrafraction tumor motion during fiducial-based liver stereotactic radiotherapy via an iterative closest point (ICP) algorithm. Radiat Oncol 2019;14:185. [PMID: 31665054 DOI: 10.1186/s13014-019-1401-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Prayongrat A, Kobashi K, Ito YM, Katoh N, Tamura M, Dekura Y, Toramatsu C, Khorprasert C, Amornwichet N, Alisanant P, Shirato H, Shimizu S. The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients. Radiotherapy and Oncology 2019;135:100-6. [DOI: 10.1016/j.radonc.2019.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhu C, Wang L, Cai Y, Wang G, Xu H, Wan Y, Zheng Q. Enhanced radiation effect on SMCC7721 cells through endoplasmic reticulum stress induced by C225-GNPs in vitro and in vivo. Oncol Lett 2018;15:4221-8. [PMID: 29552105 DOI: 10.3892/ol.2018.7864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
5 Tanguturi SK, Niemierko A, Wo JY, Nguyen KN, Prichard H, Zhu AX, Wolfgang JA, Hong TS. Gallbladder toxicity and high-dose ablative-intent radiation for liver tumors: Should we constrain the dose? Practical Radiation Oncology 2017;7:e323-9. [DOI: 10.1016/j.prro.2017.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Li S, Fujino M, Ichimaru N, Kurokawa R, Hirano S, Mou L, Takahara S, Takahara T, Li XK. Molecular hydrogen protects against ischemia-reperfusion injury in a mouse fatty liver model via regulating HO-1 and Sirt1 expression. Sci Rep 2018;8:14019. [PMID: 30232347 DOI: 10.1038/s41598-018-32411-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
7 Gill S, Liu DM, Green HM, Sharma RA. Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200941] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Knox JJ, Cleary SP, Dawson LA. Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. JCO 2015;33:1835-44. [DOI: 10.1200/jco.2014.60.1153] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
9 Kellock T, Liang T, Harris A, Schellenberg D, Ma R, Ho S, Yap WW. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment. Br J Radiol 2018;91:20170118. [PMID: 29334232 DOI: 10.1259/bjr.20170118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Bocedi A, Ingrosso G, Cattani G, Miceli R, Ponti E, Lancia A, Baldelli S, Guidi A, Ciriolo MR, Mattei M, Ricci G. The impact of ionizing irradiation on liver detoxifying enzymes. A re-investigation. Cell Death Discov 2019;5:66. [PMID: 30774994 DOI: 10.1038/s41420-019-0148-8] [Reference Citation Analysis]
11 Ching-ning Chong C, Lai-hung Wong G; 1 Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. . AIMS Medical Science 2016;3:162-78. [DOI: 10.3934/medsci.2016.1.162] [Reference Citation Analysis]
12 Zhang HJ, Zhu XF. Clinical implementation of stereotactic body radiation therapy in pancreatic cancer and hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(25): 3989-3996 [DOI: 10.11569/wcjd.v23.i25.3989] [Reference Citation Analysis]
13 Lock M, Chow R, Jayatilaka A, Plotnick M, Stephens R, Nguyen T, Fisher B, Wong E, Gaede S. Does stereotactic body radiation improve outcomes compared to conventional radiation for liver cancer patients? Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.04.002] [Reference Citation Analysis]
14 Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. Technol Cancer Res Treat 2018;17:1533033818790217. [PMID: 30068240 DOI: 10.1177/1533033818790217] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
15 Janoray G, Mornex F. Suivi après radiothérapie stéréotaxique des tumeurs hépatiques : revue de la littérature et recommandations. Cancer/Radiothérapie 2015;19:573-81. [DOI: 10.1016/j.canrad.2015.05.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 LoBianco FV, Krager KJ, Carter GS, Alam S, Yuan Y, Lavoie EG, Dranoff JA, Aykin-Burns N. The Role of Sirtuin 3 in Radiation-Induced Long-Term Persistent Liver Injury. Antioxidants (Basel) 2020;9:E409. [PMID: 32403251 DOI: 10.3390/antiox9050409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
18 Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases. International Journal of Radiation Oncology*Biology*Physics 2016;95:1175-83. [DOI: 10.1016/j.ijrobp.2016.02.045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
19 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
20 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
21 Shao Y, Song X, Jiang W, Chen Y, Ning Z, Gu W, Jiang J. MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma. Mol Ther 2019;27:355-64. [PMID: 30503969 DOI: 10.1016/j.ymthe.2018.11.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
22 Dar AR, McKillop I, Vickress J, Lock M, Yartsev S. Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy. Cureus 2018;10:e3714. [PMID: 30788203 DOI: 10.7759/cureus.3714] [Reference Citation Analysis]
23 Koukourakis MI, Giatromanolaki A, Zois CE, Kalamida D, Pouliliou S, Karagounis IV, Yeh TL, Abboud MI, Claridge TD, Schofield CJ, Sivridis E, Simopoulos C, Tokmakidis SP, Harris AL. Normal tissue radioprotection by amifostine via Warburg-type effects. Sci Rep 2016;6:30986. [PMID: 27507219 DOI: 10.1038/srep30986] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
24 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
25 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
26 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 86] [Article Influence: 24.8] [Reference Citation Analysis]
27 Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol 2019;19:66-71. [PMID: 31517072 DOI: 10.1016/j.ctro.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Hasan S, Abel S, Uemura T, Verma V, Koay EJ, Herman J, Thai N, Kirichenko A. Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. HPB 2020;22:770-8. [DOI: 10.1016/j.hpb.2019.10.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
29 Brook OR, Thornton E, Mendiratta-Lala M, Mahadevan A, Raptopoulos V, Brook A, Najarian R, Sheiman R, Siewert B. CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors. Gastroenterol Res Pract 2015;2015:126245. [PMID: 26221135 DOI: 10.1155/2015/126245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
30 Loi M, Comito T, Franzese C, Dominici L, Lo Faro L, Clerici E, Franceschini D, Mancosu P, Reggiori G, Gallo P, Badalamenti M, Scorsetti M. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. J Cancer Res Clin Oncol 2021;147:927-36. [PMID: 32945972 DOI: 10.1007/s00432-020-03389-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Lin H, Li X, Liu Y, Hu Y. Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma. ANZ J Surg. 2018;88:E718-E724. [PMID: 29399938 DOI: 10.1111/ans.14387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. J Gastrointest Cancer 2018;49:463-9. [PMID: 28710606 DOI: 10.1007/s12029-017-9990-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
33 Yu J, Li N, Tang Y, Wang X, Tang Y, Wang SL, Song YW, Liu YP, Li YX, Jin J. Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases. J Surg Oncol 2019;119:532-8. [PMID: 30609038 DOI: 10.1002/jso.25361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Ismael HN, Denbo J, Cox S, Crane CH, Das P, Krishnan S, Schroff RT, Javle M, Conrad C, Vauthey J, Aloia T. Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. Eur J Surg Oncol 2016;42:1591-6. [PMID: 27296729 DOI: 10.1016/j.ejso.2016.05.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
36 Koukourakis MI, Giatromanolaki A, Fylaktakidou K, Sivridis E, Zois CE, Kalamida D, Mitrakas A, Pouliliou S, Karagounis IV, Simopoulos K, Ferguson DJP, Harris AL. SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Invest New Drugs 2018;36:773-81. [PMID: 29387992 DOI: 10.1007/s10637-018-0566-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Hojo H, Raturi V, Nakamura N, Arahira S, Akita T, Mitsunaga S, Nakamura M, Motegi A, Kageyama SI, Zenda S, Okumura M, Ikeda M, Akimoto T. Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma. Pract Radiat Oncol 2020;10:e264-71. [PMID: 31585204 DOI: 10.1016/j.prro.2019.09.012] [Reference Citation Analysis]
38 Keane FK, Tanguturi SK, Zhu AX, Dawson LA, Hong TS. Radiotherapy for liver tumors. Hepat Oncol 2015;2:133-46. [PMID: 30190993 DOI: 10.2217/hep.15.7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Kobashi K, Prayongrat A, Kimoto T, Toramatsu C, Dekura Y, Katoh N, Shimizu S, Ito YM, Shirato H. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. J Radiat Res 2018;59:i50-7. [PMID: 29538699 DOI: 10.1093/jrr/rry018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92-99. [PMID: 28257902 DOI: 10.1016/j.jhep.2017.02.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 22.6] [Reference Citation Analysis]
41 Lam T, Wong W, Lee C, Cheung C. Transarterial chemoembolisation plus stereotactic body radiotherapy as conversion therapy for large right lobe hepatocecullar carcinoma. Surgical Practice 2021;25:211-7. [DOI: 10.1111/1744-1633.12530] [Reference Citation Analysis]
42 Barillot I, Antoni D, Bellec J, Biau J, Giraud P, Jenny C, Lacornerie T, Lisbona A, Marchesi V, Mornex F, Supiot S, Thureau S, Noel G. Bases référentielles de la radiothérapie en conditions stéréotaxiques pour les tumeurs ou métastases bronchopulmonaires, hépatiques, prostatiques, des voies aérodigestives supérieures, cérébrales et osseuses. Cancer/Radiothérapie 2018;22:660-81. [DOI: 10.1016/j.canrad.2018.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
43 Nabavizadeh N, Waller JG, Fain R, Chen Y, Degnin CR, Elliott DA, Mullins BT, Patel IA, Dyer BA, Fakhoury K, Naugler WE, Farsad K, Tanyi JA, Fuss M, Thomas CR, Hung AY. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment. International Journal of Radiation Oncology*Biology*Physics 2018;100:577-85. [DOI: 10.1016/j.ijrobp.2017.11.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]